Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mesenchymal stromal cell characteristics vary depending on their origin.
Wegmeyer H, Bröske AM, Leddin M, Kuentzer K, Nisslbeck AK, Hupfeld J, Wiechmann K, Kuhlen J, von Schwerin C, Stein C, Knothe S, Funk J, Huss R, Neubauer M. Wegmeyer H, et al. Among authors: broske am. Stem Cells Dev. 2013 Oct 1;22(19):2606-18. doi: 10.1089/scd.2013.0016. Epub 2013 Jun 22. Stem Cells Dev. 2013. PMID: 23676112 Free PMC article.
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.
Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C. Vey N, et al. Among authors: broske am. Oncotarget. 2016 May 31;7(22):32532-42. doi: 10.18632/oncotarget.8687. Oncotarget. 2016. PMID: 27081038 Free PMC article. Clinical Trial.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D. Cassier PA, et al. Among authors: broske am. Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12. Lancet Oncol. 2015. PMID: 26179200 Clinical Trial.
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
Smart K, Bröske AM, Rüttinger D, Mueller C, Phipps A, Walz AC, Ries C, Baehner M, Cannarile M, Meneses-Lorente G. Smart K, et al. Among authors: broske am. Clin Pharmacol Ther. 2020 Sep;108(3):616-624. doi: 10.1002/cpt.1964. Epub 2020 Jul 24. Clin Pharmacol Ther. 2020. PMID: 32575160 Free PMC article.
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.
Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, Gottwald S, Rae R, Lechner S, Bayer C, Dekempe Q, Osl F, Carrié N, Kassem S, Lorenz S, Christopeit T, Carpy A, Bujotzek A, Bröske AM, Dekhtiarenko I, Attig J, Kunz L, Cremasco F, Adelfio R, Fertig G, Dengl S, Gassner C, Bormann F, Kirstenpfad C, Kraft T, Diggelmann S, Knobloch M, Hage C, Feddersen R, Heidkamp G, Pöschinger T, Mayoux M, Bernasconi L, Prosper F, Dumontet C, Martinet L, Leclair S, Xu W, Paiva B, Klein C, Umaña P. Eckmann J, et al. Among authors: broske am. Blood. 2025 Jan 9;145(2):202-219. doi: 10.1182/blood.2024025987. Blood. 2025. PMID: 39476124 Free article.
Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy.
Kraxner A, Braun F, Cheng WY, Yang TO, Pipaliya S, Canamero M, Andersson E, Harring SV, Dziadek S, Bröske AE, Ceppi M, Tanos T, Teichgräber V, Charo J. Kraxner A, et al. Front Immunol. 2024 Jul 5;15:1352632. doi: 10.3389/fimmu.2024.1352632. eCollection 2024. Front Immunol. 2024. PMID: 39035007 Free PMC article.
Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S, Kraxner A, Cheng WY, Ou Yang TH, Flores M, Theiss N, Tsao TS, Andersson E, Harring SV, Bröske AE, Ceppi M, Teichgräber V, Charo J. Dziadek S, et al. Front Immunol. 2024 Mar 15;15:1352615. doi: 10.3389/fimmu.2024.1352615. eCollection 2024. Front Immunol. 2024. PMID: 38558814 Free PMC article.
12 results